TYPE 1 INTERFERON DIAGNOSTIC

摘要

The present disclosure encompasses type-I IFN and IFNa-induced PD marker expression profiles, kits, and methods for identifying such IFNa-induced PD marker expression profiles. The type-I IFN and IFNa-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNa-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNa activity, and in diagnosing or providing a prognosis to patients having IFNa-induced disorders.